TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Mike Kelliher, an officer at Ardelyx, Inc. (NASDAQ:ARDX), has sold 14,522 shares of the company’s common stock, according to a recent SEC filing. The shares were sold on May 20, 2025, at an average price of $4.0814 per share, totaling approximately $59,270. The transaction comes as the stock trades roughly 50% below its 52-week high of $8.06. This transaction was executed as part of an automatic sell-to-cover arrangement to fulfill tax obligations related to the vesting of restricted stock units. Following this transaction, Kelliher holds 282,158 shares of Ardelyx stock. According to InvestingPro analysis, Ardelyx appears undervalued at current levels, with analysts maintaining a strong buy consensus and setting price targets significantly above current trading levels. The company maintains a healthy balance sheet with a current ratio of 4.12, indicating strong liquidity. For deeper insights into Ardelyx’s valuation and 8 additional key ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Ardelyx Inc . reported its first-quarter 2025 financial results, revealing a net loss of $0.17 per share, which was below the forecasted loss of $0.11 per share. The company’s revenue reached $74.1 million, missing the anticipated $78.09 million, despite a 61% year-over-year growth driven by strong sales of its key products, IBSRELA and XPOVIO. Additionally, Raymond (NSE:RYMD) James downgraded Ardelyx’s stock rating from "Strong Buy" to "Outperform" and lowered the price target from $13.00 to $11.00, citing weaker-than-expected net sales and increased spending in sales, general, and administrative expenses.
Ardelyx presented new data on its FDA-approved drug IBSRELA at the Digestive Disease Week Conference, highlighting its benefits for patients with irritable bowel syndrome with constipation. The company also shared interim safety data from a Phase 3 study of tenapanor in pediatric patients, reporting no serious adverse events. Despite missing earnings forecasts, Ardelyx remains optimistic, maintaining its 2025 guidance for IBSRELA net sales between $240 million and $250 million and aiming for peak sales of $750 million for XPOVIO. The company is also exploring corporate development and licensing opportunities to enhance its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.